Myasthenogenicity in the main immunogenic region of acetylcholine receptor as modified by conformational design: an approach to antigenic synthetic peptides

Myasthenogenic regions in the acetylcholine receptor (AChR) α-subunit were studied in view of the conformation-dependent B-cell epitope expected at β-turn and the MHC class II-restricted T-cell epitope expected at α-helix. Torpedo AChR α67–76 and α107–116 were synthetized as the main immunogenic reg...

Full description

Saved in:
Bibliographic Details
Published inJournal of the neurological sciences Vol. 109; no. 2; pp. 182 - 187
Main Authors Takamori, Masaharu, Hamada, Toshio, Okumura, Sei'ichi
Format Journal Article
LanguageEnglish
Published Shannon Elsevier B.V 01.06.1992
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Myasthenogenic regions in the acetylcholine receptor (AChR) α-subunit were studied in view of the conformation-dependent B-cell epitope expected at β-turn and the MHC class II-restricted T-cell epitope expected at α-helix. Torpedo AChR α67–76 and α107–116 were synthetized as the main immunogenic region and the site specific for T-cell epitope in Lewis rat, respectively. Model peptides, synthetized by combining these natural sequence segments or by intervening the segment aligned as Asn-Pro-Gly-Gly (NPGG) in natural sequence segments, were tested in terns of antigenic conformation. The model peptide, α107–116·α67–76·α107–116, was immunogenic in the induction of the animal model of myasthenia, accompanied by the anti-peptide antibody cross-reactive with the native AChR. High antigenicity in antibody assays for various peptide- and native AChR-immunized rats was found when the model peptides, α107–116·α67–76 and/or α107–116·NPGG·α67–76 were used for measurement as antigens. Antigenic conformation for the induction of the disease may thus be different from that for the reactivity to antibody.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-510X
1878-5883
DOI:10.1016/0022-510X(92)90166-I